Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma 1Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Meningioma 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Hemangiopericytoma, Malignant 1Central Nervous System Neoplasms 1Brain Neoplasms 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

Temozolomide 30Radiotherapy 21Etoposide 9Carboplatin 9Bevacizumab 9Cyclophosphamide 8Vincristine 7Radiation 7Filgrastim 7Cisplatin 7Magnetic Resonance Spectroscopy 6Irinotecan 5Ifosfamide 5Granulocyte Colony-Stimulating Factor 5etoposide phosphate 4X-Rays 4Specimen Handling 4Phantoms, Imaging 4Lomustine 4Everolimus 4selpercatinib 3larotrectinib 3Thalidomide 3Paclitaxel 3Nuclear Medicine Department, Hospital 3Methotrexate 3Erlotinib Hydrochloride 3Chemotherapy, Adjuvant 3Celecoxib 3Bortezomib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Central Nervous System Neoplasms × vatalanib × Clear all
NCT00348790 2018-10-26

Vatalanib in Treating Patients With Recurrent or Progressive Meningioma

Northwestern University

Phase 2 Completed
25 enrolled 10 charts
CNSSarcoma

Hemangiopericytoma, Malignant, Brain Neoplasms, Meningioma, Sarcoma, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡